Sector News

Stada starts talks with bidders Advent, Cinven

February 14, 2017
Life sciences

Stada Arzneimittel AG Monday said it has begun talks with Cinven Partners LLP and Advent International Corporation, two separate bidders interested in acquiring up to 100% of the German pharmaceutical company.

The company said it received expressions of interest from both Cinven and Advent International and has initiated talks to allow them to discuss strategies and a potential offer price.

Stada said late Sunday it was weighing an approach from Cinven that valued its stock at 3.5 billion euros ($3.7 billion), as well as an approach from a second potential bidder that it didn’t name at the time. The Cinven offer had an indicative price of EUR56 per share, Stada said.

Shares surged 14% higher at the start of trading Monday on the news.

“Both legally non-binding expressions of interest (from the companies), which the Executive Board considered for some time, could offer in different ways attractive opportunities in the interest of the company,” Stada said.

Stada, which makes the cold treatment Grippostad, has been long been considered a possible takeover target for bigger rivals and private-equity firms. It had revenue of EUR2.12 billion in 2015.

By Sarah Sloat

Source: MarketWatch

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach